Discordant Response to Nivolumab Plus Ipilimumab and Identification of BRAF V600E Mutation in Biphasic Malignant Pleural Mesothelioma: Case Report

Discordant Response to Nivolumab Plus Ipilimumab and Identification of BRAF V600E Mutation in Biphasic Malignant Pleural Mesothelioma: Case Report

Therapeutic advancement for malignant pleural mesothelioma (MPM) has been limited. Combination immunotherapy with nivolumab plus ipilimumab is a frontline treatment option for advanced MPM that is typically deployed for patients with sarcomatoid or biphasic MPM. Here, we present a case of biphasic M...

Full description

Saved in:
Bibliographic Details
Main Authors: Olivia Wilkins, DO, Adedamola Omogbehin, MD, Peter J. Bergquist, MD, Chul Kim, MD, MPH, Stephen V. Liu, MD, Joshua E. Reuss, MD
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:JTO Clinical and Research Reports
Subjects:
Case report
Malignant pleural mesothelioma
BRAF V600E
Dabrafenib
Trametinib
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364325000360
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items